SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) today announced the full commercial launch of its complete Cytogenetic Solution, which combines the high-density SNP Array 6.0 with a simple assay and intuitive software. The microarray-based solution provides cytogenetic researchers with an efficient and accurate method of detecting chromosomal abnormalities associated with congenital diseases such as autism and mental retardation.
